Interní Med. 2005; 7(12): 551-556
Diagnosis and treatment of migraine
- Neurologická klinika 3. LF UK a FN KV, Praha
Migraine is a paroxysmal chronic disease presenting with typical headaches and a specific course of attacks. It has its trigger factors and associated signs and symptoms. Since there is no specific laboratory test that would definitely migraine confirm or rule out, a thorough history is essential. The treatment of migraine is divided into acute – suppressing the pain during attacks, and prophylactic that can decrease frequency and often times the intensity of attacks as well. For acute treatment drugs of choice are specific antimigraine medications – triptanes. The severity of attacks and associated symptoms influence the choice of application route. When choosing an appropriate prophylactic medication we should consider associated diseases, frequency of attacks and also duration of attacks.
Keywords: Key words: primary headaches, history, aura, trigger factors, acute treatment, specific antimigraine medications, triptanes, prophylactic treatment.
Published: January 1, 2006 Show citation
References
- Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA, Visser WH, and the Rizatriptan Wafer Protocol 049 Study Group. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 1999; 19: 525-530.
Go to original source... 
Go to PubMed... - Anonymus. Zomig (Zolmitriptan), International Monograph. Cheshire: Zeneca Pharmaceutical, 1997; 97.
- Diamond S, Kudrow L, Stevens J, Sharpiro DB. Long-term study of propranolol in thetreatment of migraine. Headache 1982; 22: 268-271. Go to original source... Go to PubMed...
- Doležil D, Doležal T. Naratriptanum. REMEDIA 13, 2003; 308-311.
- Donáth V. Preventívna liečba migrény. Neurologie pro praxi 2003; 2: 63-66.
- Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans in acute migraine treatment: a meta analysis of 53 trials. Lancet 2001; 358: 1668-1675. Go to original source... Go to PubMed...
- Gallagher RM. Emergency treatment of intractable migraine. Headache 1986; 26: 74-75. Go to original source... Go to PubMed...
- Goldstein J, Ryan R, Jiang K, eds. Crossover Comparison of Rizatriptan 5 mg and 10 mg versus Sumatriptan 25 mg and 50 mg in Migraine. Headache 1998; 38: 737-747. Go to original source...
- Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders. Cephalalgia, Volume 24, Supplement 1, 2004; str. 24-25, 31-32.
- Klapper JA, Stanton JS. The emergency treatment of acute migraine headache: A comparison of intravenous dihydroergotamine, dexamethasone, and placebo. Cephalagia 1991; 11: 159-160. Go to original source...
- Kotas R, a kol. Migréna, patofyziologie a léčba. Praha. Maxdorf, 2001; str. 109, 121-122.
- Kozubski W. Metamizole and hydrocortisone for the interruption of a migraine attacks-preliminary study. Headache 1992; 3: 326-328.
- Lipton RB, Studie DISC, JAMA 2000; 284 (20): 2599-2605.
- Longmore J. Pharmacology and Preclinical Mechanisms of Action of Rizatriptan. In: Bousser MG. Rizatriptan: A new Milestone in Migraine Treatment. MSD Satellite Symposium Nice 1998, France. Whitehouse Station, USA: Merk, 1998: 6.
- Lugaresi A, Montagna P, Gallari R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. Eur neurol 1988; 28: 208-211. Go to original source... Go to PubMed...
- Mastík J. Migréna - nová mezinárodní klasifikace a moderní léčebné postupy. Neurologie pro praxi 2004; 2: 79-83.
- Medová E. Léčiva používaná v terapii migrény. REMEDIA 3/2003: 223-228.
- Migraine - Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 1989; 29: 633-638. Go to original source...
- Migraine - Nimodipine European Study (MINES). European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache 1989; 29: 639-642. Go to original source...
- Nuti A, Lucetti C, Pavese N, Dell´Agnello G, Rossi G, Bonuccelli U. Long term follow-up after flunarizine or nimodipine discontinuation in migraine patiens. Cephalalgia 1996; 16: 337-340. Go to original source... Go to PubMed...
- Peatfield R, Dodick D.W. Fast Facts - Headaches. August 2003., str. 63-72. D. Go to original source...
- Ramadan NM, Schulte LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 1997; 17: 73-80. Go to original source... Go to PubMed...
- Seymour D. (a komentář Waberžinek): Soudobé názory na léčbu migrény. Medicína po promoci, roč. 2, 4/2001: str. 59-65.
- Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia 1996; 17: 67-72. Go to original source... Go to PubMed...
- Silberstein D, Saper JR, Freitag G: Migraine: Diagnosis and treatment. In Wolffś Headache and other head pain. Seventh edition. USA: Oxford University Press 2001: str. 174.
- Teall J, Tuchman M, Cutler N, eds. Rizatriptan (MAXALT) for the Acute Treatment of Migraine and Migraine Recurrence. A Placebo-Controlled, Outpatient Study. Headache 1998; 38: 173-183. Go to original source... Go to PubMed...
- The International 311 C90 Long-term Study Group. The Long-term Tolerability and Efficacy of Oral Zolmitriptan (Zomig, 311 C90) in the Acute Treatment of Migraine. An International Study. Headache 1998; 38: 173-183. Go to original source...
- Waberžinek G. Bolesti hlavy. Nakladatelství Triton, 2000: str. 79.